Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)

Inclusion Criteria:

• Male and female subjects ages 18 to 75 years with clinical diagnosis of chronicplaque psoriasis and stable disease for at least 6 months prior to the study.

• BSA involvement ≥ 3% and ≤ 20%

• A PGA score of 2 (mild), 3 (moderate) or 4 (severe) at screening and baseline

• Females of child bearing potential and male subjects who are engaging in sexualactivity that could lead to pregnancy agree to follow the specified contraceptiveguidance throughout the study, including screening, during the treatment period, andfor at least 4 weeks after the last exposure to study treatment

• Capable of giving written informed consent

Exclusion Criteria:

• Psoriasis other than plaque variant

• Any sign of infection of any of the psoriatic lesions

• Concurrent conditions or history of other diseases:

• Immunocompromised at Screening

• Chronic or acute infection requiring treatment with systemic antibiotics,antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior tothe Baseline visit

• Acute active bacterial, fungal, or viral (herpes simplex, herpes zoster, chickenpox) skin infection within 1 week prior to the Baseline visit

• Significant dermatologic or inflammatory condition other than plaque psoriasis that,in the Investigator's opinion, would make it difficult to interpret data orassessments during the study

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 1.5x the upperlimit of normal (ULN)

• Total bilirubin > 1.5 x ULN; total bilirubin > ULN and ≤ 1.5 x ULN is acceptable ifbilirubin is fractionated and direct bilirubin < 35%

• Corrected QT interval > 475

• Current or chronic history of liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones), presence ofhepatitis B surface antigen (HBsAg), or positive hepatitis C antibody test result,or a positive anti-hepatitis B core antigen (anti-HBc) result

• Ultraviolet (UV) light therapy or prolonged exposure to natural or artificialsources of UV radiation within 4 weeks prior to the Baseline visit and/or plans tohave such exposures during the study which could potentially impact the subject'spsoriasis

• Use of any prohibited medication within the indicated period before the first doseof study drug

• Within a minimum of 5 half-lives for biologic agents:

• Within 4 weeks for systemic immunosuppressive or immunomodulating agents,fumaric acid derivatives, vitamin D3 and analogs, retinoids, psolarens,corticosteroids, adrenocorticotropic hormone analogs, and tazarotene

• 2 weeks for immunizations with a live viral component; drugs known to possiblyworsen psoriasis, unless on a stable dose for > 12 weeks

• With the exception of non-medicated emollients, 2 weeks for topical treatmentsincluding corticosteroids, immunomodulators, anthralin (dithranol), vitamin Dderivatives or coal tar.

• Pregnant females or lactating females

• History of sensitivity to the study drugs, or components thereof or a history ofdrug or other allergy that, in the opinion of the Investigator or Medical Monitor,contraindicates the subject's participation in the study

• The subject has received an investigational product within 30 days, 5 half-lives, ortwice the duration of the biological effect of the study drug (whichever is longer)prior to first dose of study drug

• Current or a history of cancer within 5 years except for fully excised skin basalcell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix

• Subjects with active infection that required oral, intramuscular, or intravenousadministration of antibiotics, antifungal or antiviral agents within 7 days ofBaseline/Day 1

• Previous known participation in a clinical study with tapinarof

• Evidence of significant hepatic, renal, respiratory, endocrine, hematologic,neurologic, psychiatric, or CV system abnormalities or laboratory abnormality thatwill affect the health of the subject or interfere with interpretation of theresults